Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

52.34  -0.2 (-0.38%)

After market: 52.34 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to EXAS. EXAS was compared to 557 industry peers in the Biotechnology industry. The financial health of EXAS is average, but there are quite some concerns on its profitability. EXAS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EXAS has reported negative net income.
In the past year EXAS had a positive cash flow from operations.
In the past 5 years EXAS always reported negative net income.
In multiple years EXAS reported negative operating cash flow during the last 5 years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

With a decent Return On Assets value of -17.86%, EXAS is doing good in the industry, outperforming 78.82% of the companies in the same industry.
The Return On Equity of EXAS (-42.55%) is better than 68.94% of its industry peers.
Industry RankSector Rank
ROA -17.86%
ROE -42.55%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

EXAS has a Gross Margin of 69.02%. This is amongst the best in the industry. EXAS outperforms 81.87% of its industry peers.
EXAS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EXAS has been increased compared to 1 year ago.
EXAS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EXAS is higher compared to a year ago.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

EXAS has an Altman-Z score of 1.24. This is a bad value and indicates that EXAS is not financially healthy and even has some risk of bankruptcy.
EXAS has a Altman-Z score of 1.24. This is in the better half of the industry: EXAS outperforms 68.22% of its industry peers.
The Debt to FCF ratio of EXAS is 15.69, which is on the high side as it means it would take EXAS, 15.69 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 15.69, EXAS belongs to the top of the industry, outperforming 91.56% of the companies in the same industry.
A Debt/Equity ratio of 0.97 indicates that EXAS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.97, EXAS is not doing good in the industry: 77.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 15.69
Altman-Z 1.24
ROIC/WACCN/A
WACC7.38%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 2.73 indicates that EXAS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.73, EXAS is doing worse than 67.86% of the companies in the same industry.
EXAS has a Quick Ratio of 2.38. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS has a worse Quick ratio (2.38) than 69.30% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.38
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for EXAS have decreased strongly by -317.42% in the last year.
The Revenue has grown by 11.57% in the past year. This is quite good.
EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.78% yearly.
EPS 1Y (TTM)-317.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.86%

3.2 Future

EXAS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.14% yearly.
The Revenue is expected to grow by 10.21% on average over the next years. This is quite good.
EPS Next Y89.86%
EPS Next 2Y44.1%
EPS Next 3Y29.98%
EPS Next 5Y22.14%
Revenue Next Year12.81%
Revenue Next 2Y12.78%
Revenue Next 3Y12.49%
Revenue Next 5Y10.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 122.99 indicates a quite expensive valuation of EXAS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 88.15% of the companies listed in the same industry.
EXAS is valuated expensively when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 122.99
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaply inside the industry as 91.02% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, EXAS is valued cheaply inside the industry as 92.10% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 66.2
EV/EBITDA 227.88
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

EXAS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as EXAS's earnings are expected to grow with 29.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.1%
EPS Next 3Y29.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXAS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXACT SCIENCES CORP

NASDAQ:EXAS (6/18/2025, 8:00:01 PM)

After market: 52.34 0 (0%)

52.34

-0.2 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners98.12%
Inst Owner Change-1.1%
Ins Owners0.84%
Ins Owner Change4.1%
Market Cap9.87B
Analysts85.29
Price Target70.68 (35.04%)
Short Float %5.73%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-715.5%
Min EPS beat(2)-1391.93%
Max EPS beat(2)-39.07%
EPS beat(4)2
Avg EPS beat(4)-339.36%
Min EPS beat(4)-1391.93%
Max EPS beat(4)72.6%
EPS beat(8)5
Avg EPS beat(8)-153.52%
EPS beat(12)9
Avg EPS beat(12)-93.28%
EPS beat(16)10
Avg EPS beat(16)-73.52%
Revenue beat(2)1
Avg Revenue beat(2)0.18%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.62%
Revenue beat(4)1
Avg Revenue beat(4)-0.87%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)0.62%
Revenue beat(8)2
Avg Revenue beat(8)-0.38%
Revenue beat(12)6
Avg Revenue beat(12)1.08%
Revenue beat(16)10
Avg Revenue beat(16)1.57%
PT rev (1m)0%
PT rev (3m)-2.42%
EPS NQ rev (1m)-17.38%
EPS NQ rev (3m)-54.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.73%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)2.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 122.99
P/S 3.49
P/FCF 66.2
P/OCF 30.51
P/B 4.12
P/tB N/A
EV/EBITDA 227.88
EPS(TTM)-5.51
EYN/A
EPS(NY)0.43
Fwd EY0.81%
FCF(TTM)0.79
FCFY1.51%
OCF(TTM)1.72
OCFY3.28%
SpS14.99
BVpS12.71
TBVpS-5.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.86%
ROE -42.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.02%
FCFM 5.27%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 15.69
Debt/EBITDA 48.39
Cap/Depr 81.18%
Cap/Sales 6.17%
Interest Coverage N/A
Cash Conversion 671.19%
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.38
Altman-Z 1.24
F-Score4
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-317.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y89.86%
EPS Next 2Y44.1%
EPS Next 3Y29.98%
EPS Next 5Y22.14%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.86%
Revenue Next Year12.81%
Revenue Next 2Y12.78%
Revenue Next 3Y12.49%
Revenue Next 5Y10.21%
EBIT growth 1Y30.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year320.62%
EBIT Next 3Y82.5%
EBIT Next 5Y50.87%
FCF growth 1Y150%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y467.79%
OCF growth 3YN/A
OCF growth 5YN/A